Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2017 May 3;16(7):1324–1334. doi: 10.1158/1535-7163.MCT-16-0685

Figure 6. Non-competitive binding of Gp2 variants against InsR.

Figure 6

HEK293T pLenti-InsR-GFP cells were trypsinized and pre-incubated with either 1 μM of insulin or IGF-II for 1 hour before labeling with 100 nM Gp2 variants, followed by AF647-conjugated anti-His antibody. Binding was measured using flow cytometry. Results represented adjusted median ± standard deviation in triplicates, where the basal values were subtracted from all samples. Paired two-tailed t tests were used to compare Gp2-labeled versus ligands-Gp2-labeled samples. NS, not significant; **, p<0.01.